文献速递白血病造血干细胞移植与细胞治疗

儿童复发或难治性急性淋巴细胞白血病接受奥加伊妥珠单抗治疗后嵌合抗原受体T细胞治疗的结局

Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2022-10-30

这项国际回顾性分析纳入39例在CART-19治疗前接受奥加伊妥珠单抗(InO)桥接治疗的儿童及年轻成人复发/难治性B细胞前体急性淋巴细胞白血病患者,34例(87.2%)获得完全缓解,中位随访18.2个月,12个月无事件生存率为53.3%(95%CI 38.7-73.4),总生存率为77.8%(95%CI 64.5-93.9);17例(44%)复发,中位复发时间159天(范围28-655天)。

要点

  • 39例患儿中34例(87.2%)获得完全缓解。
  • 12个月无事件生存率53.3%(95%CI 38.7-73.4),总生存率77.8%(95%CI 64.5-93.9)。
  • 17例(44%)复发,中位复发时间159天(范围28-655天)。

核心结论

  • 在CART-19前接受InO治疗的患者,其缓解率及总生存/无事件生存与未接受InO暴露的已发表CART-19治疗数据相似。

研究设计与样本

  • 国际回顾性分析,纳入39例在T细胞采集前(n=12)和/或后(n=27)接受InO作为CART-19桥接治疗的儿童及年轻成人复发/难治性B细胞前体急性淋巴细胞白血病患者,输注时中位年龄13岁(范围1.4-23岁)。

主要发现

  • 39例中34例(87.2%)获得完全缓解。
  • CART-19输注后中位随访18.2个月,12个月无事件生存率为53.3%(95%CI 38.7-73.4),总生存率为77.8%(95%CI 64.5-93.9)。
  • 17例(44%)复发,复发中位时间为CART-19输注后159天(范围28-655天)。
  • 在采集前或后接受InO的患者之间,第28天微小残留病阴性完全缓解率、12个月总生存/无事件生存率及CD19阳性或阴性复发发生率均无差异。

关键数值与推荐

  • 与未接受InO暴露的已发表CART-19治疗数据相比,CART-19前接受InO治疗患者的缓解及总生存/无事件生存相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T cells targeting CD19 (CART-19) have shown remarkable efficacy for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). We investigated whether prior use of inotuzumab ozogamicin (InO), an anti-CD22 antibody conjugated to calicheamicin, may impact CAR T-cell manufacturing or efficacy via pre-CART-19 depletion of the B-cell compartment. In this international, retrospective analysis, 39 children and young adults receiving InO before (n = 12) and/or after (n = 27) T-cell apheresis as bridging therapy to CART-19 treatment were analyzed. Median age at infusion was 13 years (range 1.4-23 years). Thirty-four out of 39 patients (87.2%) obtained complete remission. With a median follow-up of 18.2 months after CART-19 infusion, 12-month event-free survival (EFS) was 53.3% (95% confidence interval (CI): 38.7-73.4) and overall survival (OS) was 77.8% (95% CI: 64.5-93.9). Seventeen patients (44%) relapsed with a median of 159 days (range 28-655) after CART-19 infusion. No difference in day 28 minimal residual disease negative complete response rate, 12-month OS/EFS, or incidence of CD19-positive or -negative relapses was observed among patients receiving InO before or after apheresis. Compared to published data for patients treated with CART-19 therapy without prior InO exposure, response and OS/EFS for patients treated with InO prior to CART-19 are similar.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ceolin V, Brivio E, van Tinteren H, et al. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia. 2022. PMID: 36310183. doi:10.1038/s41375-022-01740-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。